Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
01
2022
accepted:
20
04
2022
entrez:
10
5
2022
pubmed:
11
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
The resurgence of COVID-19 cases since June 2021, referred to as the fourth COVID-19 wave, has led to the approval and administration of booster vaccines. Our study aims to identify any associations between vaccine status with the characteristics and outcomes of patients hospitalized with severe COVID-19 disease. We retrospectively reviewed all COVID-19 patients admitted to a large tertiary center between July 25 and October 25, 2021 (fourth wave in Israel). Univariant and multivariant analyses of variables associated with vaccine status were performed. Overall, 349 patients with severe or critical disease were included. Patients were either not vaccinated (58%), had the first two vaccine doses (35%) or had the booster vaccine (7%). Vaccinated patients were significantly older, male predominant, and with a higher number of comorbidities including diabetes, hyperlipidemia, ischemic heart disease, heart failure, immunodeficient state, kidney disease and cognitive decline. Time from the first symptom to hospital admission was longer among non-vaccinated patients (7.2 ± 4.4 days, p = 0.002). Critical disease (p<0.05), admissions to the intensive care unit (p = 0.01) and advanced oxygen support (p = 0.004) were inversely proportional to the number of vaccines given, lowest among the booster vaccine group. Death (20%, p = 0.83) and hospital stay duration (8.05± 8.47, p = 0.19) were similar between the groups. Hospitalized vaccinated patients with severe COVID-19 had significantly higher rates of most known risk factors for COVID-19 adverse outcomes. Still, all disease outcomes were similar or better compared with the non-vaccinated patients.
Sections du résumé
BACKGROUND
The resurgence of COVID-19 cases since June 2021, referred to as the fourth COVID-19 wave, has led to the approval and administration of booster vaccines. Our study aims to identify any associations between vaccine status with the characteristics and outcomes of patients hospitalized with severe COVID-19 disease.
METHODS
We retrospectively reviewed all COVID-19 patients admitted to a large tertiary center between July 25 and October 25, 2021 (fourth wave in Israel). Univariant and multivariant analyses of variables associated with vaccine status were performed.
FINDINGS
Overall, 349 patients with severe or critical disease were included. Patients were either not vaccinated (58%), had the first two vaccine doses (35%) or had the booster vaccine (7%). Vaccinated patients were significantly older, male predominant, and with a higher number of comorbidities including diabetes, hyperlipidemia, ischemic heart disease, heart failure, immunodeficient state, kidney disease and cognitive decline. Time from the first symptom to hospital admission was longer among non-vaccinated patients (7.2 ± 4.4 days, p = 0.002). Critical disease (p<0.05), admissions to the intensive care unit (p = 0.01) and advanced oxygen support (p = 0.004) were inversely proportional to the number of vaccines given, lowest among the booster vaccine group. Death (20%, p = 0.83) and hospital stay duration (8.05± 8.47, p = 0.19) were similar between the groups.
CONCLUSION
Hospitalized vaccinated patients with severe COVID-19 had significantly higher rates of most known risk factors for COVID-19 adverse outcomes. Still, all disease outcomes were similar or better compared with the non-vaccinated patients.
Identifiants
pubmed: 35536849
doi: 10.1371/journal.pone.0268050
pii: PONE-D-22-00969
pmc: PMC9089907
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0268050Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Ann Intern Med. 2021 Aug;174(8):1073-1080
pubmed: 34000201
Clin Infect Dis. 2021 May 18;72(10):e558-e565
pubmed: 32856034
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
BMJ. 2020 May 22;369:m1923
pubmed: 32444358
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Infection. 2021 Jun;49(3):401-410
pubmed: 33389708
Vaccines (Basel). 2021 Jul 13;9(7):
pubmed: 34358197
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
Euro Surveill. 2021 Feb;26(6):
pubmed: 33573712
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Med Virol. 2022 Jan;94(1):291-297
pubmed: 34491575
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Lancet. 2021 Jul 17;398(10296):223-237
pubmed: 34274064
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Clin Infect Dis. 2021 Dec 6;73(11):2112-2115
pubmed: 33993265
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
BMJ. 2020 May 22;369:m1985
pubmed: 32444460